Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. The company’s focus is on those disorders that are associated with a steroid hormone called cortisol. The company is developing mifepristone - a potent glucocorticoid receptor II (GR-II) antagonist that modulates the activity of cortisol - for the treatment of various severe metabolic, psychiatric, and oncologic disorders. It has also discovered three series of novel selective GR-II antagonists and intends to move one or more of the new compounds from these series into clinical development in 2014. Cushing’s Syndrome The United States Food and Drug Administration (FDA) approved Korlym (mifepristone) 300 mg Tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The FDA approval means that the company could market the drug for the approved indication in the United States. Psychotic Depression The company is also developing mifepristone, Korlym’s active ingredient, for treatment of the psychotic features of psychotic depression under a patent license from Stanford University. The FDA has granted ‘fast track’ status to evaluate the safety and efficacy of mifepristone for the treatment of the psychotic features of psychotic depression. The company has an ongoing Phase 3 study of mifepristone, the active ingredient in Korlym, for the psychotic features of psychotic depression. Triple-Negative Breast Cancer In January 2014, the company began a Phase 1 study of mifepristone in combination with the chemotherapy drug eribulin in the treatment of triple-negative breast cancer – a form of cancer with a particularly poor prognosis. There is no FDA-approved treatment for either of these illnesses. Antipsychotic-Induced Weight Gain Mitigation The company announced positive results from its clinical proof-of-concept study in lean healthy male volunteers evaluating the ability of mifepristone to mitigate weight gain associated with the use of Zyprexa. The combination of Zyprexa or Risperdal and mifepristone is not approved for any indication. Selective GR-II Receptor Antagonists Several of the company’s new compounds have demonstrated positive results in animal or in vitro models for the prevention and reversal of alcohol dependence; amyotrophic lateral sclerosis (Lou Gehrig’s disease); Alzheimer’s disease; anti-psychotic-induced weight gain; breast, ovarian and prostate cancer (in combination with a chemotherapeutic agent); electroconvulsive-induced retrograde amnesia; metabolic syndrome; muscular dystrophy; obesity; prevention of glucocorticoid-induced neurological damage in premature infants; and post-traumatic stress disorder. One of these new compounds, CORT 108297, has completed Phase 1 trials and the company might explore its potential use in psychiatric and other central nervous system disorders. The company expected to begin Phase 1 studies in one or more of its new compounds during 2014. Research and Development The company incurred $20.5 million of research and development expenses in the year ended December 31, 2013. Intellectual Property The company has six U.S. method-of-use applications covering certain GR-II antagonists, including the treatment of patients suffering from mental disorders by optimizing mifepristone absorption; neurological damage in premature infants; muscular dystrophy; diseases using combination steroid and glucocorticoid receptor antagonist therapy; depression in patients taking Interleukin-2; and amyotrophic lateral sclerosis. The approximate expiration dates of the patents that could issue from these applications and their foreign counterparts range from 2023 to 2032. The company has six United States composition of matter patents containing claims relating to three series of novel selective GR-II antagonists, with an additional such patent pending. Three of these patents have issued in Europe, with applications for three more pending. The expiration dates of these U.S. and European patents range from 2026 to 2032. Competition The company competes with Novartis. History Corcept Therapeutics Incorporated was founded in 1998. The company was incorporated in the state of Delaware in 1998.
corcept therapeutics inc
149 Commonwealth Drive
Menlo Park, CA 94025
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.